Major depressive disorder is a mood disorder characterized by the occurrence of one or more major depressive episodes associated with clinically significant distress or impairment in personal, family, social, academic or occupational functioning. In the DSM-5-TR diagnostic system, the diagnosis also requires that a manic or hypomanic episode has never occurred and that the presentation is not better explained by a schizophrenia spectrum disorder or another psychotic disorder, nor attributable to the physiological effects of a substance or another medical condition.
It is essential to distinguish the disorder from the episode. A major depressive episode is a time limited clinical syndrome defined by the concurrent presence of specific affective, cognitive, neurovegetative and psychomotor symptoms. Major depressive disorder, by contrast, is the nosological diagnosis made on the basis of one or more such episodes and exclusion of conditions that would indicate different diagnoses. The same depressive syndrome may in fact occur in bipolar disorder, substance or medication related disorders and depressive disorders due to medical conditions, without implying the presence of major depressive disorder.
Terminology is not perfectly superimposable across the major classification systems. The DSM-5-TR uses the category major depressive disorder, distinguishing single episode and recurrent forms. ICD-11 from the World Health Organization instead organizes the corresponding presentations mainly into single episode depressive disorder, code 6A70, and recurrent depressive disorder, code 6A71. The two classifications share the fundamental clinical core but differ in the formulation of diagnostic requirements, severity grading and organization of specifiers.
Major depressive disorder is among the leading causes of disease related distress and disability worldwide. Epidemiological estimates vary considerably according to the population studied, diagnostic criteria, instruments used and the method by which previous episodes are identified. International reviews generally place twelve month prevalence at around 4 to 5% of the global adult population, whereas lifetime prevalence estimates are higher and particularly sensitive to ascertainment methods. Prevalence is on average about twice as high in women as in men from adolescence onward, although the disorder may affect people of any sex, age and sociocultural background.
Onset is possible at any stage of life, from childhood to old age, but occurs frequently during adolescence and young adulthood. An apparently unipolar depressive onset in adolescence or early adulthood requires particular attention to the possibility of a later bipolar presentation, especially when there is a family history of bipolar disorder, recurrent episodes with early onset, mixed features or other suggestive clinical elements. A newly occurring depressive episode in later life instead warrants careful investigation for concomitant medical, neurological and medication related conditions.
The course is extremely heterogeneous. In community studies many episodes resolve over several months and most remit within one year, whereas clinical samples more often include prolonged episodes, incomplete remissions and recurrences. Loss of the full episode criteria does not necessarily coincide with complete functional recovery: sleep disturbances, fatigue, cognitive difficulties, anhedonia and reduced social or occupational functioning may persist as residual symptoms, which in turn are associated with a higher likelihood of subsequent relapse or recurrence.
In the DSM-5-TR, major depressive disorder is diagnosed as single episode when only one major depressive episode has been documented over the lifetime, and as recurrent when at least two distinct episodes have occurred. For two consecutive episodes to be considered separate, there must have been at least two consecutive months during which the full criteria for a major depressive episode were not met. This distinction has prognostic and therapeutic relevance because the number of previous episodes contributes to estimating recurrence risk and deciding the duration of maintenance treatment.
The disorder is also associated with a substantial increase in the risk of suicidal behavior. Suicidal ideation may range from passive thoughts of death to intent, planning and highly lethal attempts. There is, however, no single percentage that appropriately describes individual risk: it changes dynamically with episode severity, previous attempts, hopelessness, agitation, insomnia, psychotic symptoms, substance use, comorbidity, access to lethal means, social support and many other factors. Risk assessment is therefore not an isolated act performed at diagnosis but a repeated component of clinical management.
No single necessary and sufficient etiological cause of major depressive disorder has been identified. Genetic, epidemiological, neurobiological and psychological evidence indicates a multifactorial condition in which biological predisposition and environmental exposures interact to determine the probability that a person will develop a depressive episode. It is therefore scientifically incorrect to reduce major depression to a single neurochemical alteration, a single gene, a specific traumatic event or a particular anatomical brain abnormality.
This distinction is also important nosologically. When a depressive syndrome is judged to be a direct pathophysiological consequence of a specific medical disease, or is induced by a substance or medication, diagnostic classifications provide categories other than major depressive disorder. Endocrine, neurological, autoimmune, infectious or neoplastic diseases may be associated with depressive symptoms through different biological and psychological mechanisms, but simple temporal coexistence does not demonstrate a direct etiological relationship, and many physical illnesses instead represent risk factors or comorbidities.
Genetic predisposition is supported by family, twin and genomic studies. The heritability of major depressive disorder is moderate and is generally estimated at about 30 to 40%, a value clearly incompatible with a simple Mendelian model. Large genome wide association studies have identified hundreds of loci associated with depression and confirm a highly polygenic architecture: numerous common variants, each with a very small individual effect, contribute to susceptibility together with environmental factors. No genetic variant currently has sufficient accuracy to be used as an individual diagnostic test.
Genetic susceptibility does not act independently of the environment. Risk is higher in people exposed to early adversity, childhood maltreatment, stressful life events, violence, loss of significant relationships, social isolation, financial hardship and persistent stress. These associations are probabilistic rather than deterministic: many people exposed to severe events do not develop depression, and some patients with major depressive disorder report no clearly identifiable precipitating event. Stressors should therefore be interpreted in the context of individual vulnerability and not as a necessary diagnostic condition.
Other factors associated with higher risk include female sex, family history of mood disorders, anxiety disorders, persistent insomnia, problematic substance use, chronic pain and numerous physical illnesses. Endocrine and reproductive transitions may modify vulnerability in some individuals, as occurs during the peripartum period, but etiology remains multifactorial even in these settings. Social, cultural and health care factors also influence exposure to stress, access to care and the likelihood that the disorder will be recognized.
At the pathogenetic level, one of the historically most influential hypotheses has concerned monoamine systems, particularly serotonin, norepinephrine and dopamine. The fact that many effective antidepressants alter monoaminergic transmission demonstrates the pharmacological relevance of these systems, but does not demonstrate that the disorder is caused by a simple “serotonin deficiency” or deficiency of another monoamine. Clinical heterogeneity, the mismatch between immediate changes in synaptic monoamine availability and the timing of clinical response, and the efficacy of interventions with different mechanisms make a purely monoaminergic explanation insufficient.
Current models place particular emphasis on synaptic plasticity and the capacity of neural networks to modify their structure and function in response to experience. Glutamatergic signaling, NMDA and AMPA receptors, neurotrophic factors such as BDNF and intracellular pathways involved in synapse formation and stabilization have been implicated in the pathophysiology and effects of several antidepressant treatments. The rapid antidepressant properties of glutamatergic interventions have strengthened interest in these mechanisms, without identifying a single glutamatergic abnormality shared by all patients.
Chronic stress may influence many of these pathways through the hypothalamic pituitary adrenal axis. Alterations in cortisol secretion and glucocorticoid feedback have been observed in subgroups of patients, especially in more severe, melancholic or psychotic forms. Prolonged exposure to stress hormones may interact with synaptic plasticity, sleep, metabolism, immune function and brain circuits involved in emotional processing. Here again, however, stress axis abnormalities are heterogeneous and are neither a necessary finding nor a diagnostic test.
Another area of research concerns inflammation. Meta analyses have found, on average, higher concentrations of some inflammatory markers, including C reactive protein and several cytokines, in groups of depressed patients than in controls. The effect is variable and strongly influenced by obesity, smoking, physical activity, comorbid diseases, medications and other confounders. Inflammation therefore appears to characterize a biological subgroup of patients and may interact with tryptophan metabolism, neurotransmission, endothelial function and neuronal plasticity, but no inflammatory marker is currently sufficiently specific to diagnose depression or systematically guide its treatment.
Circadian systems and sleep architecture are also closely linked to depression. Insomnia and hypersomnia may be symptoms of the episode as well as factors associated with its onset and persistence. Some patients show alterations in circadian timing, sleep continuity and sleep wake regulation. The clinical relevance of these systems is further suggested by the efficacy, in selected settings, of light therapy and interventions targeting the sleep wake rhythm, especially in presentations with a seasonal pattern.
At the group level, neuroimaging studies show functional and, in some studies, structural differences within circuits including the prefrontal cortex, anterior cingulate cortex, amygdala, hippocampus, striatum and brain networks involved in reward, salience, emotion regulation and self referential thinking. These findings are not characteristic lesions of the disorder and show substantial overlap with healthy populations and other psychiatric disorders. Conventional magnetic resonance imaging therefore cannot confirm or exclude a diagnosis of major depressive disorder in an individual patient.
These network alterations nevertheless provide plausible models for understanding part of the pathophysiology. Abnormal functioning of reward circuits may contribute to anhedonia and loss of motivation; changes in prefrontal and cingulate networks may contribute to concentration deficits, cognitive rigidity and difficulty regulating emotions; excessive negative self referential processing may sustain rumination and self devaluation. The relationship is not one to one, however, and the same symptoms may arise from different combinations of mechanisms.
Psychological phenomena represent another level of pathogenesis, complementary rather than alternative to the biological level. Negative cognitive biases, rumination, reduced reward sensitivity, dysfunctional emotion regulation strategies and avoidance behaviors may contribute to symptom persistence. A patient who progressively stops rewarding activities and social relationships, for example, may receive progressively less positive reinforcement from the environment, promoting a cycle of anhedonia, inactivity and further loss of motivation. These mechanisms are among the targets of cognitive and behavioral psychotherapies.
Clinically manifest pathophysiology therefore arises from the dynamic interaction among genetic predisposition, brain development, life experiences, stress, neuroendocrine and immune regulation, synaptic plasticity, sleep, cognitive processes and the social environment. The final consequence is not a single dysfunction but a disturbance of systems regulating affective tone, motivation, pleasure, cognition, behavior, sleep, appetite and the stress response. This biological heterogeneity helps explain why patients who meet the same diagnostic criteria may have very different clinical presentations and respond differently to the same treatment.
Despite the enormous amount of biological data available, no genetic, endocrine, immunological, neurochemical, electrophysiological or neuroimaging biomarker has achieved validation sufficient to replace clinical assessment. Abnormalities observed in population studies are primarily research findings and should not be improperly converted into individual causal explanations. The diagnosis of major depressive disorder therefore remains a clinical diagnosis based on symptoms, course, functional impairment and differential diagnosis.
Clinical assessment begins with the history, which should reconstruct chronologically the change from the patient’s usual functioning. It is not sufficient to ask generally whether the person “feels depressed”, because some patients mainly describe loss of interest, fatigue, insomnia, cognitive difficulties, irritability or somatic complaints. Mood and the capacity to experience pleasure and interest should therefore be explored systematically, defining time of onset, duration, continuity of symptoms, any diurnal fluctuations and consequences for daily activities.
Depressed mood may be described as sadness, emptiness, hopelessness, dejection or inability to envision positive prospects. In some patients, a sense of emotional numbness predominates rather than clearly perceived sadness. In children and adolescents the affective symptom may present predominantly as irritability. Irritability is common in adults but, in DSM-5-TR criteria, does not replace the depressed mood requirement specifically allowed for younger patients.
The other cardinal symptom is anhedonia, meaning a marked reduction in interest or pleasure. Previously rewarding activities may be abandoned or performed without emotional engagement; the patient may reduce social relationships, interests, sexual activity and personal initiatives. Anhedonia is not simply fatigue: it may persist even when the patient is physically capable of an activity but neither anticipates nor experiences the usual reward.
The history should then explore neurovegetative symptoms. Sleep may be characterized by difficulty falling asleep, repeated awakenings, early morning awakening or, in other patients, hypersomnia. Appetite may decrease with consequent weight loss or increase, sometimes with a particular craving for carbohydrates and weight gain. The opposite direction of manifestations across different patients highlights the heterogeneity of the disorder and is also reflected in clinical specifiers such as melancholic or atypical features.
Loss of energy is very common and may be described as persistent fatigue, a sense of heaviness, reduced exercise tolerance or the need for disproportionate effort to perform ordinary activities. It should be distinguished, as far as possible, from sleepiness, medication induced sedation and fatigue secondary to physical illness. In some people, reduced motivation and fatigability lead to a marked reduction in personal hygiene, meal preparation and other self care activities.
Psychomotor changes include retardation or agitation sufficiently evident to be observable by other people. With retardation, the patient may move slowly, speak with increased latency and give brief responses, whereas in agitated forms the patient may be unable to sit still, wring the hands, pace repeatedly or show intense restlessness. A purely subjective feeling of being slowed down or restless does not automatically meet the formal psychomotor criterion.
Cognitive symptoms frequently include reduced attention, difficulty concentrating, indecisiveness, slowed thinking and working memory difficulties. The patient may report being unable to read, follow a conversation, work with previous efficiency or make even simple decisions. In older adults cognitive disturbances may be particularly prominent and require differential assessment for neurocognitive disorders, while remembering that depression and neurodegeneration may also coexist.
Depressive cognitions often include self devaluation, feelings of worthlessness, excessive or inappropriate guilt, pessimism and hopelessness. Guilt may concern real mistakes appraised disproportionately or unrealistic responsibilities. In severe forms these ideas may reach delusional intensity, for example with fixed beliefs of guilt, ruin, illness or condemnation. The presence of psychotic symptoms changes severity and treatment strategy and should be actively investigated.
Assessment of suicidal ideation should be explicit. A wish not to wake up or passive thoughts of death should be distinguished from active suicidal ideation, intent, planning, preparations and previous attempts. Access to means, impulsivity, substance use, recent worsening, agitation, hopelessness and protective factors should be explored. Asking directly about suicide does not suggest the behavior and is a routine part of the assessment of a depressive episode.
Alongside symptoms of the current episode, the entire longitudinal mood history should be reconstructed. It is necessary to ask whether there have been distinct past periods characterized by unusually elevated or markedly irritable mood associated with increased energy or activity, reduced need for sleep, rapid speech, grandiosity, increased goal directed activity, distractibility or impulsive behavior. A history compatible with mania or hypomania substantially changes the diagnostic formulation and points toward the bipolar spectrum.
Previous depressive episodes, age at onset, duration, possible seasonality, functional recovery, hospitalizations, suicidal behavior and response to treatments should also be reconstructed. A family history of depression, bipolar disorder, psychosis, substance use and suicide may provide clinically relevant information. When possible and with the patient’s consent, information from family members or cohabitants may be particularly useful in identifying previous hypomanic periods that the patient had not interpreted as pathological.
The medication and substance use history should include prescribed drugs, over the counter products, psychoactive substances and temporal relationships between exposure and symptoms. Alcohol, stimulants, sedatives and other substances may produce or worsen depressive manifestations. Medications capable, under appropriate circumstances, of contributing to mood symptoms should also be considered, while avoiding automatically attributing depression to a drug solely on the basis of temporal association.
The medical history should investigate endocrine, neurological and systemic disorders, chronic pain, sleep disorders, cardiovascular, metabolic and inflammatory diseases and other conditions capable of coexisting with depression or producing overlapping symptoms. Particular attention should be paid to recent changes in health status, focal neurological symptoms, endocrine abnormalities, unexplained weight loss, fever, cognitive decline and other manifestations that make an isolated primary psychiatric disorder less likely.
After the history, a mental status examination is performed. Observation begins with general appearance, hygiene, eye contact, attitude, cooperation and psychomotor behavior. Speech may be reduced in quantity, volume and prosody or may be essentially normal. The patient’s reported mood is compared with observed affect, assessing its range, reactivity, congruence and stability.
Thought is assessed in both form and content. Slowed thinking, rumination, pessimism, guilt, hopelessness and thoughts of death may emerge. The presence of delusions or hallucinations requires defining the temporal relationship between psychosis and mood disturbance: psychotic symptoms limited to depressive episodes may be compatible with major depression with psychotic features, whereas psychosis persisting outside mood episodes requires consideration of other diagnoses.
Attention, orientation, memory, executive functions, insight and judgment are then assessed. There is no neuropsychological profile specific to depression, but cognitive difficulties may contribute substantially to disability and warrant further investigation especially in older people or when they persist after affective remission.
The general physical and neurological examination is tailored to age, clinical history and symptoms. It may include vital signs, nutritional and hydration status, signs of endocrine disease, neurological assessment and investigation of relevant systemic manifestations. Physical examination is not intended to “prove” major depressive disorder but may identify concomitant conditions, alternative diagnoses or factors relevant to treatment choice and safety.
The diagnosis of major depressive disorder is clinical. There is no pathognomonic blood, genetic, electroencephalographic or neuroimaging test, and no currently available biomarker has sufficient sensitivity and specificity to confirm or exclude the disorder in an individual patient. The diagnostic process should therefore follow a rational sequence: recognize the depressive syndrome, immediately assess safety, verify episode requirements, reconstruct the longitudinal course, exclude bipolarity and other alternative diagnoses, identify relevant medical conditions or substances, and finally define severity and clinical features.
The first step, when depression is suspected, is to determine whether symptoms represent a clinically significant change from usual functioning. Occasional sadness, insomnia, fatigue or reduced motivation does not amount to a major depressive episode. Number of symptoms, duration, persistence, intensity and functional impairment should be considered together.
At the same time, the possible need for urgent intervention should be assessed. Suicidal ideation with intent or planning, a recent attempt, inability to ensure one’s own safety, severe self neglect, refusal of food or fluids, catatonia, severe psychotic symptoms or marked agitation may require urgent psychiatric assessment and, in some circumstances, treatment in a protected setting.
For the DSM-5-TR, the diagnostic core is the presence of a major depressive episode. The criteria should be applied in their entirety and not reduced to the simple score of a self report scale.
DSM-5-TR criteria for a major depressive episode
Once the episode has been identified, a DSM-5-TR diagnosis of major depressive disorder additionally requires exclusion of schizophrenia spectrum conditions or other psychotic disorders that better explain the presentation, and there must be no history of a manic or hypomanic episode. This last step is fundamental: a person may present for assessment only during a depressive phase and may not spontaneously report previous periods of mood elevation or pathological increases in energy.
The presence during a depressive episode of some manic or hypomanic symptoms that are insufficient to constitute a full episode may permit use of the with mixed features specifier. This specifier identifies a clinically important presentation associated with a greater likelihood of bipolar features over the course of illness, but it does not automatically amount to a diagnosis of bipolar disorder. If a true manic or hypomanic episode is documented, the diagnosis of major depressive disorder should instead be reconsidered.
ICD-11 uses a partly different classification framework. The depressive presentation is defined by the presence for at least two weeks of a characteristic set of affective, cognitive, behavioral and neurovegetative symptoms, with significant functional impairment, except in exceptional circumstances in which a particularly severe presentation may be recognized before two weeks have elapsed. The classification then distinguishes single episode depressive disorder from recurrent depressive disorder and specifies severity and features. ICD-11 requirements should not be regarded as a literal translation of DSM-5-TR criteria.
After the presence of the syndrome has been established, the course must be determined. In the DSM-5-TR, the disorder may be single episode or recurrent. Two episodes are considered distinct when separated by at least two consecutive months during which the full criteria for a major depressive episode were not met. Remission status and severity of the current presentation should also be recorded, considering the number and intensity of symptoms and the degree of functional impairment.
Diagnostic characterization includes specifiers, which describe clinical phenotypes with prognostic or therapeutic implications without turning them into separate disorders.
The with seasonal pattern specifier requires a regular temporal relationship between the onset of major depressive episodes and a particular season, and complete remission must also show a characteristic seasonal relationship. During the past two years, seasonal depressive episodes demonstrating this relationship must have occurred without nonseasonal episodes during the same period, and over the entire course seasonal episodes must substantially outnumber nonseasonal episodes. The pattern must not be better explained by psychosocial circumstances that recur seasonally. Onset in autumn or winter with remission in spring is the most typical form, but it is not the only possible pattern.
Standardized scales such as the PHQ-9 may be used for screening, quantifying symptom burden and monitoring over time. In specialist settings, clinician rated scales such as the Hamilton Depression Rating Scale or Montgomery-Åsberg Depression Rating Scale may be used. These instruments improve systematic symptom measurement but do not replace the diagnostic interview: a high score indicates probability or greater severity of depressive symptoms and does not independently establish the presence of major depressive disorder.
Laboratory tests should be selected according to history, age, physical examination, medications and the pretest probability of alternative diagnoses. There is no mandatory laboratory panel for every patient with depression. When clinically indicated, a complete blood count, electrolytes, renal and liver function tests, TSH and, where appropriate, thyroid hormones, vitamin B12 or folate and other targeted tests may be appropriate. Toxicology testing, pregnancy testing, infectious disease investigations or more extensive endocrine assessment are ordered when the history and clinical presentation make them relevant.
Neuroimaging, electroencephalography, neuropsychological assessment and additional neurological investigations are not routinely performed to diagnose depression. They become appropriate in the presence of focal neurological signs, seizures, atypical or rapidly progressive cognitive changes, personality changes, confusional state, head injury, unusual late onset or other findings suggesting structural brain disease or a neurological disorder.
The priority differential diagnosis is bipolar disorder. Bipolar depression may be clinically indistinguishable from a unipolar major depressive episode if only the current phase is observed. Diagnosis therefore depends on the longitudinal history. A family history of bipolar disorder, early onset, numerous episodes, mixed features, previous treatment associated mood switches and other features may increase suspicion, but none replaces the clinical documentation of mania or hypomania required for bipolar classification.
Persistent depressive disorder should be considered when chronic depressive symptoms predominate according to the temporal requirements of the classification. Adjustment disorder with depressed mood is instead linked to an identifiable stressor and is diagnosed when the presentation meets the specific requirements for adjustment disorder and is not better explained by another mental disorder. The distinction cannot be based simply on the presence or absence of a stressful event, because a major depressive episode may occur after adverse events.
Bereavement is not an automatic exclusion for a major depressive episode. A physiological response to loss may include intense sadness, insomnia, reduced appetite and thoughts focused on the deceased person, but a major depressive episode may occur in the context of bereavement when its criteria are met. Prolonged grief disorder should also be distinguished, as it has its own criteria and phenomenology and may coexist with major depression.
Other psychiatric differential diagnoses include anxiety disorders, post traumatic stress disorder, substance related disorders, psychotic disorders, schizoaffective disorder and neurocognitive disorders. When psychotic symptoms are present, the temporal relationship between psychosis and mood changes becomes decisive for differential diagnosis.
Numerous medical conditions may produce fatigue, insomnia, slowing, cognitive difficulties, reduced appetite or other overlapping symptoms. Thyroid dysfunction, anemia, nutritional deficiencies, sleep disorders, neurological disease and systemic illnesses should be considered when suggested by the clinical context. It is nevertheless necessary to distinguish a concomitant illness, which increases risk or modifies the presentation of depression, from a condition directly responsible for the affective syndrome.
The diagnostic process concludes with a clinical formulation that should not be limited to the nosological label. Single or recurrent episode, severity, remission, any specifiers, suicidal behavior, psychiatric and physical comorbidities, functioning, precipitating and perpetuating factors, previous treatment responses, social support and patient preferences should be documented. These elements determine the subsequent individualized treatment plan.
Treatment of major depressive disorder should be defined through a shared assessment of severity, episode features, suicide risk, functional impairment, comorbidities, previous treatments and preferences. There is no identical treatment sequence for all patients. Major contemporary guidelines agree on the use of structured psychotherapies, antidepressants and integrated interventions, while recommendations for individual options vary according to severity and clinical context.
Before treatment is started, safety, diagnosis and possible bipolar features should be reassessed. In patients with significant suicide risk, a safety plan should be established, monitoring increased, support persons involved when appropriate and access to potentially lethal means restricted. When risk cannot be managed safely in an outpatient setting, or when there is severe self neglect, catatonia, severe psychosis or inability to eat, inpatient treatment may be necessary.
Psychoeducation accompanies every level of treatment. The patient should understand the episodic or recurrent nature of the disorder, treatment goals, realistic response times, the importance of adherence and the possibility of adverse effects or discontinuation symptoms. Sleep, daily activities, alcohol and other substance use, social support, concomitant medical conditions and practical barriers to accessing care should also be addressed.
In less severe forms, especially when risk and functional impairment are limited, NICE guidelines recommend not routinely offering an antidepressant as initial treatment if the patient does not prefer it. Low or high intensity psychological interventions may be used according to the presentation, including cognitive behavioral approaches, behavioral activation and other validated psychotherapies. The intensity of intervention should nevertheless be increased when response is insufficient or the clinical presentation worsens.
Cognitive behavioral therapy is among the most extensively studied psychotherapies. It targets patterns of thought and behavior that contribute to the persistence of depression and has strong evidence of efficacy. Behavioral activation and interpersonal psychotherapy are also empirically supported. Choice depends on availability, preferences, clinical features, previous responses and service expertise. In recurrent forms, cognitive and mindfulness based strategies may also be used in programs aimed at relapse prevention.
When depression is more severe, persistent or substantially disabling, structured psychotherapy, pharmacotherapy or their combination is indicated. Combining an antidepressant with psychotherapy may offer particular benefit in more complex, persistent or recurrent presentations, although the two modalities do not need to be combined systematically in every uncomplicated episode.
Antidepressants include several pharmacological classes with documented efficacy. Options frequently used as initial treatment in adults include selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors and other newer antidepressants such as bupropion, mirtazapine and vortioxetine; agomelatine is an additional option in health systems where it is available and appropriate. Average efficacy differences among many antidepressants are generally smaller than individual differences in tolerability and response.
Drug choice should therefore consider previous personal and family responses, predominant symptoms, anxiety, insomnia or hypersomnia, pain, appetite and weight, sexual function, cardiovascular and metabolic risk, pregnancy, comorbidities, drug interactions, overdose risk and patient preferences. SSRIs are often used early in clinical practice because of their balance of efficacy, tolerability and safety, but they are not the mandatory choice for every patient.
Tricyclic antidepressants and monoamine oxidase inhibitors remain effective treatments but are generally used at later stages or in specialist circumstances because of greater tolerability issues, interactions, toxicity and management complexity. Their place in second or later line strategies is particularly relevant for patients who have not benefited from better tolerated options.
After pharmacotherapy is initiated, adherence, adverse effects, symptom course, functioning and suicide risk should be monitored. An incomplete response during the first weeks does not immediately demonstrate inefficacy because antidepressants require an adequate therapeutic trial in dose and duration. The presence or absence of early improvement may inform subsequent decisions, but assessment should account for tolerability and severity of the presentation.
When response is insufficient, diagnosis, possible bipolarity, adherence, treatment dose and duration, substance use, interactions, medical conditions and psychosocial factors should be reassessed before defining the disorder as resistant. It is also necessary to distinguish a substantial absence of response from a partial response because subsequent strategies may differ.
When there is no response to an adequately administered antidepressant, switching to another antidepressant in the same or a different class may be reasonable. With a partial response, selected patients may instead benefit from continuing the partly effective treatment and adding a second pharmacological strategy or psychotherapy. CANMAT guidelines include several second generation antipsychotics, particularly aripiprazole and brexpiprazole, among augmentation strategies with strong evidence, while other agents may be selected at later lines according to the clinical presentation.
Lithium is a historically established augmentation strategy for some resistant forms and has an important role in the psychopharmacology of mood disorders. Its use nevertheless requires careful patient selection, monitoring of serum concentrations and renal and thyroid function, and assessment of drug interactions. Other combinations and augmentation strategies may be used in specialist practice, but selection should be based on available evidence and individual characteristics rather than simple empirical multiplication of medications.
The term treatment resistant depression is commonly used to describe failure to respond to at least two adequate antidepressant treatments, although definitions used in studies are not completely uniform. The broader concept of difficult to treat depression also considers symptom persistence, comorbidity, tolerability, adherence problems, psychosocial factors and the need for a prolonged, multidimensional treatment strategy.
In patients with an insufficient response to conventional treatments, repetitive transcranial magnetic stimulation may be used, including protocols based on theta burst stimulation in appropriate settings. The technique applies magnetic fields to specific cortical areas and avoids systemic drug effects. It is an established treatment for resistant depression in numerous guidelines, with protocol and target selection entrusted to centers with specific expertise.
Electroconvulsive therapy remains one of the most effective treatments for severe major depressive episodes. It is particularly important when a rapid response is required or when psychotic depression, catatonia, high suicide risk, severe refusal of food, a previous good response to electroconvulsive therapy, or nonresponse or intolerance to multiple pharmacological treatments is present. The procedure is performed under general anesthesia with medical monitoring and may cause cognitive effects, particularly amnestic effects, which should be discussed and monitored.
Interventions that modulate glutamatergic transmission have expanded treatment options for resistant presentations. Intranasal esketamine and intravenous ketamine may produce a rapid reduction in symptoms in selected patients, but require specialist protocols to manage dissociation, sedation, blood pressure changes, risk of misuse and other safety issues. Authorized indications, administration methods and requirements for combination with other antidepressants vary among jurisdictions; these treatments do not replace accurate diagnosis or a maintenance strategy.
Depression with psychotic features requires specialist management. The best supported strategies include combining an antidepressant with an antipsychotic or electroconvulsive therapy, with choice based on severity, urgency, previous responses, medical conditions and preferences. Psychotic symptoms should not be treated as a simple complication separate from the disorder, but as a feature of the episode that substantially changes its management.
Catatonia associated with a depressive episode is another situation of particular severity. It requires prompt recognition and specific treatment because immobility, behavioral abnormalities and autonomic dysfunction may have major medical consequences. In catatonic depressive presentations, electroconvulsive therapy has a central role when clinically indicated.
Light therapy has a particularly established role in depression with a seasonal pattern and may be considered in other depressive presentations according to specific protocols. Correct timing in relation to the circadian rhythm is important and, as with other antidepressant therapies, the risk of mood activation should be considered in patients with bipolar vulnerability.
Physical exercise has documented antidepressant effects and may be incorporated into the treatment plan, adapted to the patient’s physical condition and capabilities. It should not be presented as a simple motivational recommendation or as a universal substitute for psychotherapy or pharmacotherapy in severe forms. In patients with significant symptoms it is mainly an integrated therapeutic component that also provides cardiovascular, metabolic and functional health benefits.
A balanced diet, regular sleep, reduced alcohol and substance use, gradual resumption of activities and rebuilding social relationships are useful components of overall management. There is, however, no diet, supplement or nutraceutical treatment capable of replacing validated therapies for major depressive disorder. Any complementary interventions should be assessed for quality of evidence, safety and possible drug interactions.
Once remission has been achieved, the continuation phase begins, aimed at consolidating response and reducing relapse risk. Effective pharmacological treatment is generally continued for several months after remission, frequently for at least 6 to 12 months overall according to clinical features and guidelines. In patients at high risk of recurrence, for example those with multiple episodes, severe or prolonged episodes, residual symptoms, suicidality or relevant comorbidities, maintenance treatment for at least two years or longer may be appropriate.
The decision to discontinue an antidepressant should be individualized and accompanied by gradual dose reduction, because rapid discontinuation may cause withdrawal symptoms that can be mistaken for relapse. The rate of reduction should take account of the medication, treatment duration, dose, previous withdrawal symptoms and individual response.
Recurrence prevention is not exclusively pharmacological. Psychotherapy, early recognition of prodromal symptoms, regular daily rhythms, treatment of comorbidities and an agreed plan for rapid intervention if symptoms worsen are important components of follow up. In patients with recurrent episodes, continuity of care is particularly important because risk does not end with remission of the current episode.
Management should be further individualized during pregnancy and the peripartum period, in children and adolescents, in older adults and in patients with major physical illnesses. In these populations, indications, safety data, drug metabolism and the balance between treatment risk and the risk of untreated depression differ from those in the general adult population and require specific recommendations.
Future perspectives include improved biological stratification of depression, identification of response predictors, rapid acting treatments targeting synaptic plasticity, optimization of neuromodulation and study of new pharmacologically assisted psychotherapies. Approaches based on neuroimaging, inflammatory markers, genetics, pharmacogenomics or predictive algorithms are under intensive investigation, but none currently allows reliable determination of which single treatment will be effective for each patient. Psychedelic assisted therapies also remain experimental or highly regulated interventions in most health systems and indications and are not routine treatment for major depressive disorder.
Prognosis is variable. Many patients achieve complete remission, sometimes after the first episode, whereas others have a recurrent or persistent course. In community samples, the median duration of an episode is generally estimated at several months and a high proportion of episodes resolve within one year, whereas patients attending specialist services tend to have higher rates of chronicity, comorbidity and treatment resistance.
The risk of a new episode increases with the number of previous episodes. At the population level, a less favorable prognosis is also associated with greater severity, long episode duration, early onset, residual symptoms, anxiety or substance related comorbidity, physical illnesses, psychotic symptoms, suicidal behavior and incomplete treatment response. These factors cannot, however, predict the course of an individual patient with certainty.
Symptomatic remission does not necessarily coincide with full functional recovery. Concentration, motivation, occupational performance, relationships and quality of life may normalize more slowly than mood. Contemporary treatment goals therefore extend beyond reducing a symptom score to include stable remission, recovery of functioning and prevention of recurrence.
The most serious complication of major depressive disorder is suicidal behavior. Thoughts of death, ideation, planning and attempts may occur during the episode and risk may change rapidly. A previous attempt is one of the most important clinical indicators of future risk, but no single factor permits reliable individual prediction. Depressive severity, hopelessness, insomnia, agitation, psychotic symptoms, substance use, comorbidity and availability of lethal means contribute to the overall assessment.
Depression may also lead to nonsuicidal self injury, which should be distinguished from a suicide attempt according to stated intent and clinical context. The presence of self injury remains clinically important and requires a complete assessment of suicide risk and any comorbidities.
One of the most common consequences is functional impairment. Reduced energy, motivation, concentration and decision making ability may lead to work absence, reduced productivity, academic difficulties, job loss and inability to manage household or administrative activities adequately. Disability may persist even after partial symptom improvement and therefore represents a treatment target distinct from mood remission alone.
Family and social relationships may deteriorate because of progressive isolation, loss of interest, irritability, reduced communication and difficulty maintaining daily responsibilities. The resulting isolation may in turn reduce sources of support and positive reinforcement, contributing to symptom persistence and creating a perpetuating cycle between depression and social dysfunction.
Persistence of the episode and chronicity are additional unfavorable outcomes. Some patients do not achieve complete remission and continue to experience clinically relevant symptoms for prolonged periods. Subthreshold residual symptoms are also important because they may sustain disability and increase the likelihood of subsequent relapse.
Patients who achieve remission may experience relapses and recurrences. Vulnerability generally increases with the number of previous episodes and is greater in the presence of incomplete remission and comorbidity. This recurrent pattern is a possible feature of the disorder and does not necessarily represent failure of previous treatment, but it requires progressively more structured preventive strategies.
Depression and substance use disorders have a bidirectional relationship. Some patients use alcohol, sedatives, cannabis or other substances in an attempt to modulate insomnia, anxiety or emotional distress; use may subsequently worsen symptoms, impulsivity, sleep, treatment adherence and suicide risk. The presence of both conditions tends to make treatment more complex and requires integrated management.
In particularly severe forms, self neglect may occur with reduced hygiene, inadequate food and fluid intake, abandonment of treatments for concomitant illnesses and inability to meet essential needs. In frail patients and older adults these consequences may rapidly become medically significant.
Cognitive disturbances associated with depression may produce persistent difficulties in attention, memory and executive functions. Even after mood remission, some patients report residual cognitive symptoms that may hinder return to work and complete functional recovery. In older adults, significant cognitive symptoms always require careful differential diagnosis and follow up because a neurocognitive disorder may coexist with depression.
Major depressive disorder is frequently associated with chronic physical illnesses and with increased all cause mortality observed in epidemiological studies. The relationships are complex and bidirectional: cardiovascular, metabolic, oncological, neurological and painful conditions increase the risk of depression, while depression, inactivity, smoking, sleep disturbances, lower treatment adherence, metabolic factors and other mechanisms may contribute to worse physical outcomes. It is therefore incorrect to attribute the entire association to a single direct biological mechanism.
In the presence of physical illness, depression may impair medication adherence, participation in rehabilitation, nutrition, physical activity and access to care. The consequence may be mutual worsening of the two conditions, which is why treatment of depression should, when necessary, be integrated with treatment of concomitant medical diseases.
Psychotic features and catatonia deserve particular attention but, from a nosological perspective, should not simply be regarded as “complications” developing outside the episode: they represent features of particular severity that may occur within the depressive presentation and immediately alter risk assessment, care setting and treatment.
In conclusion, the main long term consequence of major depressive disorder is not only the possibility of new episodes but the interaction among recurrence, residual symptoms, suicidal behavior, social and occupational impairment, and physical and psychiatric comorbidities. Treatment focused only on initial symptom reduction is therefore insufficient: the optimal clinical outcome includes complete remission, functional recovery and prevention of recurrence.
Informational notice: the information contained on this page is provided solely for informational and educational purposes and does not replace the advice, diagnosis or treatment provided by a physician. If needed, always consult a qualified healthcare professional.
Artificial intelligence transparency: this page was created with the support of artificial intelligence tools, used to assist in the production and processing of its content.